What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

Original reporting
Published Oct 29, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$PHATNeutralMed
01

Why it matters

Near-term trading is likely driven by updated financial guidance (gross-to-net toward lower end, cash and expense ranges) and by event-risk items: Q4 Phase II top-line timing for VOQUEZNA in EoE and the outcome risk of BDR Pharmaceuticals’ lawsuit challenging FDA’s application of the GAIN Act to extend NCE exclusivity.

02

Market read

This is a company-specific earnings-call update with concrete guidance and a clear set of upcoming clinical and legal catalysts that can shift probability-weighted valuation.

03

What to watch

The margin miss is attributed to one-time manufacturing charges, so traders may discount it, but any recurrence risk is not fully quantified; also, the cash covenant discussion reduces financing overhang but does not remove future dilution risk if clinical timelines slip.

Relevance 7/10Novelty 6/10Timing: after-hours, following the Q3 earnings call

Background

The call covers commercial execution for Voquezna (vonoprazan), cash and expense guidance, upcoming Phase II/III planning for EoE and NERD, and FDA exclusivity litigation tied to the GAIN Act.

Company-level read

Ticker impact

$PHATNeutralMedium confidence
Context

Phathom guided full-year gross-to-net discount toward the lower end of 55% to 59%, and reiterated cash expense and cash runway under its financing agreement.

Expected impact

Likely modest support as investors price in lower gross-to-net discount and sufficient cash, offset by uncertainty around exclusivity litigation outcomes and timing of next clinical readouts.

Evidence & confidence

The article provides specific updated financial expectations (gross-to-net toward lower end, cash and expense guidance) plus concrete upcoming catalysts (Q4 Phase II top-line, 2027 Phase III discussion) and a named FDA exclusivity lawsuit that can affect commercial durability.

Market effects

Biopharma investors may recalibrate read-through on GI acid-blocker competitive durability and the litigation risk premium around exclusivity extensions.

Limited, primarily US small/mid-cap biotech sentiment.

Low, as the catalysts and litigation are US FDA and US commercial execution focused.

Counterpoint

Even with lower gross-to-net expectations, the stock may trade more on exclusivity litigation and the probability-weighted path to Phase III, which can dominate near-term valuation.

Key entities

  • Phathom Pharmaceuticals

    NASDAQ-listed biopharma focused on gastrointestinal treatments, principal product Voquezna (vonoprazan).

  • VOQUEZNA (vonoprazan)

    Phathom’s potassium-competitive acid blocker; subject of exclusivity litigation and upcoming EoE Phase II readouts.

  • BDR Pharmaceuticals

    Filed suit against the FDA on Oct. 21 challenging the application of the GAIN Act to extend NCE exclusivity for VOQUEZNA tablets.

  • FDA

    Previously concluded that 10 years of NCE exclusivity as extended by the GAIN Act applies to products containing vonoprazan.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.

$PHATMedAI 8/10

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G